These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3146774)

  • 1. Effects of ritanserin on sleep disturbances of dysthymic patients.
    Paiva T; Arriaga F; Wauquier A; Lara E; Largo R; Leitao JN
    Psychopharmacology (Berl); 1988; 96(3):395-9. PubMed ID: 3146774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin.
    Bersani G; Pozzi F; Marini S; Grispini A; Pasini A; Ciani N
    Acta Psychiatr Scand; 1991 Apr; 83(4):244-8. PubMed ID: 1903019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of repeated ritanserin on middle-aged poor sleepers.
    Adam K; Oswald I
    Psychopharmacology (Berl); 1989; 99(2):219-21. PubMed ID: 2508157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers.
    Viola AU; Brandenberger G; Toussaint M; Bouhours P; Paul Macher J; Luthringer R
    Clin Neurophysiol; 2002 Mar; 113(3):429-34. PubMed ID: 11897543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study to establish the indication for the selective S2 antagonist ritanserin.
    Klieser E; Strauss WH
    Pharmacopsychiatry; 1988 Nov; 21(6):391-3. PubMed ID: 3149751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sleep and 5-HT2 receptor sensitivity in recovered depressed patients.
    da Roza Davis JM; Sharpley AL; Solomon RA; Cowen PJ
    J Affect Disord; 1992 Mar; 24(3):177-81. PubMed ID: 1573126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers.
    van Laar M; Volkerts E; Verbaten M
    Psychopharmacology (Berl); 2001 Mar; 154(2):189-97. PubMed ID: 11314681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep.
    Idzikowski C; Mills FJ; Glennard R
    Brain Res; 1986 Jul; 378(1):164-8. PubMed ID: 3091188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does ritanserin, a potent serotonin-S2 antagonist, restore energetic functions during the night?
    Janssen PA
    J R Soc Med; 1987 Jul; 80(7):409-13. PubMed ID: 3116237
    [No Abstract]   [Full Text] [Related]  

  • 10. Ritanserin improves sleep quality in narcolepsy.
    Mayer G
    Pharmacopsychiatry; 2003 Jul; 36(4):150-5. PubMed ID: 12905101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of zimeldine, a selective 5-HT reuptake inhibitor, combined with ritanserin, a selective 5-HT2 antagonist, on waking and sleep stages in rats.
    Bjorvatn B; Ursin R
    Behav Brain Res; 1990 Nov; 40(3):239-46. PubMed ID: 2149499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-response study examining the effects of ritanserin on human slow wave sleep.
    Idzikowski C; Mills FJ; James RJ
    Br J Clin Pharmacol; 1991 Feb; 31(2):193-6. PubMed ID: 1904750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam.
    Bressa GM; Marini S; Gregori S
    Int J Clin Pharmacol Res; 1987; 7(2):111-9. PubMed ID: 3108171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT2 receptor antagonism and slow-wave sleep in major depression.
    Staner L; Kempenaers C; Simonnet MP; Fransolet L; Mendlewicz J
    Acta Psychiatr Scand; 1992 Aug; 86(2):133-7. PubMed ID: 1529736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slow wave sleep and 5-HT2 receptor sensitivity in generalised anxiety disorder: a pilot study with ritanserin.
    da Roza Davis JM; Sharpley AL; Cowen PJ
    Psychopharmacology (Berl); 1992; 108(3):387-9. PubMed ID: 1523288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
    Bersani G; Grispini A; Marini S; Pasini A; Valducci M; Ciani N
    Clin Neuropharmacol; 1990 Dec; 13(6):500-6. PubMed ID: 2125857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder.
    Bakish D; Lapierre YD; Weinstein R; Klein J; Wiens A; Jones B; Horn E; Browne M; Bourget D; Blanchard A
    J Clin Psychopharmacol; 1993 Dec; 13(6):409-14. PubMed ID: 8120154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep patterns in depression and anxiety: theory and pharmacological effects.
    Sandor P; Shapiro CM
    J Psychosom Res; 1994; 38 Suppl 1():125-39. PubMed ID: 7799244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of the 5-HT2 antagonist ritanserin on sleep-walking cycle in the rat.
    Silhol S; Glin L; Gottesmann C
    Pharmacol Biochem Behav; 1992 Jan; 41(1):241-3. PubMed ID: 1539075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam.
    Ceulemans DL; Hoppenbrouwers ML; Gelders YG; Reyntjens AJ
    Pharmacopsychiatry; 1985 Sep; 18(5):303-5. PubMed ID: 3931107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.